|View printer-friendly version|
Cidara Provides Corporate Update and Reports First Quarter 2020 Financial Results
"We are pleased to report that we have recently activated our first clinical trial site for the Phase 3 ReSPECT trial, which is evaluating rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT), and it is now open for enrollment," said
Recent Corporate Highlights
- Activated first ReSPECT trial site: In May, Cidara activated the first clinical trial site in its Phase 3 ReSPECT prophylaxis trial of rezafungin in patients undergoing allogeneic blood and marrow transplant.
$30Mrights offering: In February, Cidara raised $30Mthrough issuance of common and Series X Preferred stock in a rights offering that was fully backstopped by Biotechnology Value Fund, L.P.and Stonepine Capital, LP.
- Announced new data for rezafungin and CD377: In May, new clinical and preclinical data were published for rezafungin and CD377, Cidara’s antiviral conjugate (AVC) development candidate for influenza, via the virtual abstract book from the
European Congress of Clinical Microbiology and Infectious Diseases(ECCMID).
- Exploring rezafungin and Cloudbreak antiviral programs to address COVID-19 challenges: Cidara identified the potential for rezafungin, its lead antifungal candidate, to be used in the prevention of the hyperimmune response seen in critical COVID-19 patients with aspergillosis. Cidara also began evaluating AVCs identified from its Cloudbreak antiviral platform as potential coronavirus therapeutics.
- Presented at two investor conferences: Cidara presented at the 19th Annual
Needham Virtual Healthcare Conferencein April and Maxim Group’s Infectious Diseases Virtual Conferencein May.
First Quarter 2020 Financial Results
- Cash, cash equivalents and restricted cash totaled $74.3 million as of
March 31, 2020, compared with $60.3 million as of December 31, 2019.
- As of
March 31, 2020, Cidara had 40,559,511 shares of common stock outstanding, and 1,096,519 shares of Series X convertible preferred stock outstanding, which are convertible into 10,965,190 shares of common stock.
- Research and development expenses were $13.0 million for the three months ended
March 31, 2020, compared to $12.7 million for the same period in 2019. The increase was primarily attributable to clinical development activities for rezafungin.
- General and administrative expenses were $4.1 million for the three months ended
March 31, 2020, compared to $3.7 million for the same period in 2019.
- Net loss for the three months ended
March 31, 2020was $14.5 million, compared to a net loss of $16.6 million for the first quarter of 2019.
About the ReSPECT Clinical Trial
The ReSPECT trial is a global, randomized, double-blind, controlled, pivotal Phase 3 trial of rezafungin versus the standard antimicrobial regimen to prevent invasive fungal disease due to Candida, Aspergillus and Pneumocystis in subjects undergoing allogeneic BMT. Using the same once weekly dosing regimen previously used in the Phase 2 and currently used in Phase 3 treatment trials with an extended duration for 90 days, Rezafungin will be compared to a daily regimen containing multiple drugs including fluconazole or posaconazole, and trimethoprim-sulfamethoxazole, also known as Bactrim, for 90 days, at which time fungal-free survival will be measured as the primary efficacy outcome. The trial will enroll approximately 462 adults with underlying conditions, such as acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndrome(s), lymphoma and aplastic anemia, across approximately 30 BMT centers.
Cidara is developing therapeutics to improve the standard of care for patients facing severe fungal or viral infections. The Company’s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead antifungal candidate, rezafungin, in addition to therapies targeting influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to whether Cidara will be able to continue to activate clinical trials sites or timely enroll the ReSPECT trial, whether current enrollment in the ReSTORE trial represents an improved enrollment trend overall, whether the impact of the COVID-19 pandemic on the ReSTORE trial will subside and allow Cidara to predict timing for top-line data, whether rezafungin will be an effective prophylaxis against COVID-19-related fungal infections and whether Cidara will be able to attract non-dilutive financing to conduct a clinical trial for this purpose, and whether Cidara will successfully identify AVCs from its Cloudbreak antiviral platform that will be effective against COVID-19. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the availability of, and participation in, financing opportunities. These and other risks are identified in our filings with the SEC, including without limitation our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and in other filings subsequently made by Cidara with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Karen O’Shea, Ph.D.
|Condensed Consolidated Balance Sheets|
|Cash, cash equivalents, and restricted cash||$||74,314||$||60,268|
|Other current assets||6,307||5,546|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Total liabilities and stockholders' equity||$||84,097||$||68,976|
|Condensed Consolidated Statements of Operations (unaudited)|
|Three Months Ended
|(In thousands, except share and per share data)||2020||2019|
|Research and development||12,996||12,669|
|General and administrative||4,095||3,735|
|Total operating expenses||17,091||16,404|
|Loss from operations||(14,561||)||(16,404||)|
|Other income (expense):|
|Change in fair value of contingent forward purchase obligations||—||(270||)|
|Interest income, net||22||113|
|Total other income (expense)||22||(157||)|
|Net loss and comprehensive loss||$||(14,539||)||$||(16,561||)|
|Recognition of beneficial conversion feature||(2,762||)||—|
|Net loss attributable to common shareholders||$||(17,301||)||$||(16,561||)|
|Basic and diluted net loss per common share||$||(0.46||)||$||(0.58||)|
|Shares used to compute basic and diluted net loss per common share||37,856,338||28,532,176|
Source: Cidara Therapeutics, Inc.